ReviewCancer chemotherapy and pharmacology2015
Targeted therapy in cancer.
Review in Cancer chemotherapy and pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of PD-1/PD-L1 and LAG-3 immune checkpoint inhibitors in the treatment of patients with solid tumor.Frontiers in immunology · 2026Pooled it
- Pooled it
- Pharmacological Targeting of Angiogenesis in Head and Neck Cancer: Molecular Mechanisms and Emerging Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Effects of Benzo[a]pyrene on Targeted Therapy Response and Platelet-Activating Factor-Receptor-Mediated Microvesicle Particle Release in Non-Small Cell Lung Cancer.Medical sciences (Basel, Switzerland) · 2026Article
- Enhancing cancer classification accuracy with a self-attention network using panel capture sequencing data.Briefings in bioinformatics · 2026Article
- Explainable AI for Predicting Mortality Risk in Metastatic Cancer: Retrospective Cohort Study Using the Memorial Sloan Kettering-Metastatic Dataset.JMIR cancer · 2026Article
- Nucleolin as a Crucial Player in Head and Neck Cancer: Diagnostic and Therapeutic Perspectives.Current cancer drug targets · 2026Review
- Tumor heterogeneity as a driver of drug resistance and its implications for personalized therapy.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- A Holistic Review of Oncological Drug Targets and Trajectories of Resistance in Cancer Therapy.Oncology research · 2026Review
- Targeting Cell Signalling Pathways with New Small Molecules in Inflammation and Cancer.Current topics in medicinal chemistry · 2026Review
- Case Report: Long term multimodality treatment of canine hepatocellular carcinoma with serial monitoring of serum alpha-fetoprotein.Frontiers in veterinary science · 2026Article
- In vitro evaluation of hyaluronate-functionalized multi-walled carbon nanotubes containing trigonelline for their anti-cancer activity on A2780 ovarian cancer cells.Scientific reports · 2025Article
- Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.Cancer research communications · 2025Article
- Tubulin inhibitors: an insight into new strategies to combat leukemia.Future medicinal chemistry · 2025Review
- Cancer therapy resistance from a spatial-omics perspective.Clinical and translational medicine · 2025Review
- Impact of intracellular radionuclide distribution in a Monte Carlo biophysical 3D multi-cellular model for targeted alpha therapy.Medical physics · 2025Article
- Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review).International journal of oncology · 2025Review
- Article
- Targeted pancreatic cancer therapy using 4-farnesyloxycoumarin conjugated nanocrystalline cellulose and Chitosan nanoparticles.Scientific reports · 2025Article
- Stochastic pharmacodynamics of a heterogeneous tumour-cell population.Journal of pharmacokinetics and pharmacodynamics · 2025Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purposeTo describe the emergence of targeted therapies that have led to significant breakthroughs in cancer therapy and completed or ongoing clinical trials of novel agents for the treatment of patients with advanced cancer.
methodsThe literature was systematically reviewed, based on clinical experience and the use of technologies that improved our understanding of carcinogenesis.
resultsGenomics and model systems have enabled the validation of novel therapeutic strategies. Tumor molecular profiling has enabled the reclassification of cancer and elucidated some mechanisms of disease progression or resistance to treatment, the heterogeneity between primary and metastatic tumors, and the dynamic changes of tumor molecular profiling over time. Despite the notable technologic advances, there is a gap between the plethora of preclinical data and the lack of effective therapies, which is attributed to suboptimal drug development for "driver" alterations of human cancer, the high cost of clinical trials and available drugs, and limited access of patients to clinical trials. Bioinformatic analyses of complex data to characterize tumor biology, function, and the dynamic tumor changes in time and space may improve cancer diagnosis. The application of discoveries in cancer biology in clinic holds the promise to improve the clinical outcomes in a large scale of patients with cancer. Increased harmonization between discoveries, policies, and practices will expedite the development of anticancer drugs and will accelerate the implementation of precision medicine.
conclusionsCombinations of targeted, immunomodulating, antiangiogenic, or chemotherapeutic agents are in clinical development. Innovative adaptive study design is used to expedite effective drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.